Join Us for an Upcoming Webcast about SPINRAZA TM (nusinersen)

By Cure SMA | Published On December 29, 2016

Please join Cure SMA, MDA and representatives from Biogen to learn more about SPINRAZA™ (nusinersen). As you know, SPINRAZA recently received FDA approval in the U.S. for the treatment of Spinal Muscular Atrophy (SMA) in pediatric and adult patients. In order to receive an update on SPINRAZA, please join this webcast, which is intended only for U.S. audiences.

We hope you can participate on Tuesday, January 3, 2017 at 2PM EST for a discussion which will include:

  • SPINRAZA’s prescribing information, including an overview of the efficacy and safety data demonstrated in clinical trials that were evaluated by FDA
  • Information on Biogen support services for eligible SPINRAZA patients
  • Q&A

Should you be unable to join the live presentation, a recording will be available for viewing on www.curesma.org and www.mda.org for six months following the webinar.

We would like to thank the community for your tireless efforts and contributions to advance SMA research and development. We look forward to speaking with you soon.

INDICATION

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests at baseline and before each dose of SPINRAZA to monitor for early signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing at baseline and before each dose of SPINRAZA to monitor for early signs of this risk.

The most common side effects of SPINRAZA include upper and lower respiratory tract infections, complete or partial collapse of a lung or lobe of a lung, constipation, headache, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. This information is not intended to replace discussions with your healthcare provider.

Please see full Prescribing Information for additional important safety information.

SPINRAZA Launch Community Webinar

Tuesday, January 3, 2017, 2PM EST
https://attendee.gotowebinar.com/register/5186380235045413124

If you have any further questions about Biogen’s support services, please contact an SMA Support Coordinator at 1-844-4SPINRAZA (1-844-477-4672), 8:30 AM - 8:00 PM EST.

Topics: Community & Awareness, Clinical Trials, Advocacy, Front Page News

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software